We use unbiased screens to identify druggable targets to reverse viral latency. This has resulted in the identification of FDA-approved drugs to reactivate latent virus and ensures an expanding drug pipeline of putative HIV cure drugs that are extensively characterized ex vivo. The most promising strategies are selected for further in vivo development. We also assess the toxicity of these latency reversal agents in in vitro and ex vivo models.